Yanan Zhu
Stock Analyst at Wells Fargo
(2.01)
# 3,628
Out of 5,182 analysts
85
Total ratings
39.73%
Success rate
-6.14%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Yanan Zhu
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SYRE Spyre Therapeutics | Maintains: Overweight | $50 → $90 | $69.24 | +29.98% | 4 | Apr 14, 2026 | |
| CYTK Cytokinetics | Initiates: Overweight | $95 | $65.48 | +45.08% | 1 | Apr 10, 2026 | |
| QURE uniQure | Upgrades: Overweight | $15 → $60 | $17.54 | +242.08% | 7 | Mar 9, 2026 | |
| NTLA Intellia Therapeutics | Maintains: Equal-Weight | $12 → $15 | $15.87 | -5.48% | 8 | Mar 3, 2026 | |
| SRPT Sarepta Therapeutics | Maintains: Overweight | $45 → $38 | $20.42 | +86.09% | 8 | Feb 27, 2026 | |
| ACLX Arcellx | Downgrades: Equal-Weight | $115 | $115.05 | -0.04% | 1 | Feb 23, 2026 | |
| TSHA Taysha Gene Therapies | Maintains: Overweight | $8 → $11 | $6.40 | +71.88% | 4 | Jan 5, 2026 | |
| IONS Ionis Pharmaceuticals | Maintains: Overweight | $82 → $100 | $74.12 | +34.92% | 4 | Jan 5, 2026 | |
| ARCT Arcturus Therapeutics Holdings | Maintains: Overweight | $42 → $20 | $8.47 | +136.13% | 9 | Oct 23, 2025 | |
| EDIT Editas Medicine | Maintains: Equal-Weight | $3 → $4 | $3.21 | +24.61% | 7 | Sep 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $45 | $31.46 | +43.04% | 1 | Aug 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $16 → $12 | $1.43 | +739.16% | 4 | Aug 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $4 → $2.5 | $1.32 | +89.39% | 4 | Aug 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $6 → $5 | $1.53 | +226.80% | 4 | Aug 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $18 → $14 | $3.48 | +302.30% | 5 | Aug 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $75 → $70 | $30.16 | +132.10% | 3 | May 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $12 → $10 | $4.04 | +147.52% | 2 | Mar 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $70 → $65 | $55.18 | +17.80% | 1 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $30 | $8.14 | +268.55% | 1 | Apr 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $5 → $4 | $0.26 | +1,468.63% | 3 | Aug 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $450 | $2.76 | +16,204.35% | 1 | Mar 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $272 → $326 | $788.13 | -58.64% | 1 | Feb 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $79 → $70 | $10.25 | +582.93% | 2 | Oct 29, 2020 |
Spyre Therapeutics
Apr 14, 2026
Maintains: Overweight
Price Target: $50 → $90
Current: $69.24
Upside: +29.98%
Cytokinetics
Apr 10, 2026
Initiates: Overweight
Price Target: $95
Current: $65.48
Upside: +45.08%
uniQure
Mar 9, 2026
Upgrades: Overweight
Price Target: $15 → $60
Current: $17.54
Upside: +242.08%
Intellia Therapeutics
Mar 3, 2026
Maintains: Equal-Weight
Price Target: $12 → $15
Current: $15.87
Upside: -5.48%
Sarepta Therapeutics
Feb 27, 2026
Maintains: Overweight
Price Target: $45 → $38
Current: $20.42
Upside: +86.09%
Arcellx
Feb 23, 2026
Downgrades: Equal-Weight
Price Target: $115
Current: $115.05
Upside: -0.04%
Taysha Gene Therapies
Jan 5, 2026
Maintains: Overweight
Price Target: $8 → $11
Current: $6.40
Upside: +71.88%
Ionis Pharmaceuticals
Jan 5, 2026
Maintains: Overweight
Price Target: $82 → $100
Current: $74.12
Upside: +34.92%
Arcturus Therapeutics Holdings
Oct 23, 2025
Maintains: Overweight
Price Target: $42 → $20
Current: $8.47
Upside: +136.13%
Editas Medicine
Sep 3, 2025
Maintains: Equal-Weight
Price Target: $3 → $4
Current: $3.21
Upside: +24.61%
Aug 25, 2025
Initiates: Overweight
Price Target: $45
Current: $31.46
Upside: +43.04%
Aug 14, 2025
Maintains: Overweight
Price Target: $16 → $12
Current: $1.43
Upside: +739.16%
Aug 13, 2025
Maintains: Equal-Weight
Price Target: $4 → $2.5
Current: $1.32
Upside: +89.39%
Aug 13, 2025
Maintains: Overweight
Price Target: $6 → $5
Current: $1.53
Upside: +226.80%
Aug 8, 2025
Maintains: Overweight
Price Target: $18 → $14
Current: $3.48
Upside: +302.30%
May 7, 2025
Maintains: Overweight
Price Target: $75 → $70
Current: $30.16
Upside: +132.10%
Mar 12, 2025
Maintains: Overweight
Price Target: $12 → $10
Current: $4.04
Upside: +147.52%
May 9, 2024
Maintains: Equal-Weight
Price Target: $70 → $65
Current: $55.18
Upside: +17.80%
Apr 22, 2024
Initiates: Overweight
Price Target: $30
Current: $8.14
Upside: +268.55%
Aug 10, 2023
Maintains: Overweight
Price Target: $5 → $4
Current: $0.26
Upside: +1,468.63%
Mar 27, 2023
Assumes: Overweight
Price Target: $450
Current: $2.76
Upside: +16,204.35%
Feb 2, 2021
Maintains: Equal-Weight
Price Target: $272 → $326
Current: $788.13
Upside: -58.64%
Oct 29, 2020
Maintains: Overweight
Price Target: $79 → $70
Current: $10.25
Upside: +582.93%